Capece M, et al. - Experts evaluated the efficacy of collagenase clostridium histolyticum (CCH) for the treatment of Peyronie's disease (PD). Collagenase clostridium histolyticum (CCH) was the first licensed drug for the treatment of PD and was seen to be indicated in patients with palpable plaque and curvature deformity of at least 30° of curvature. Statistically significant improvement was seen in all IIEF and PDQ questionnaires subdomains. To achieve a good result and to minimize the cost of the treatment, the 3-injection protocol was effective enough.